pLX304-DCK*-GW-IRES-GFP
(Plasmid
#176289)
-
PurposeGateway vector for use in generating DCK*-POI fusion reporter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 176289 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLX304
-
Backbone manufacturerNone
- Backbone size w/o insert (bp) 11000
- Total vector size (bp) 12000
-
Modifications to backbonean IRES-GFP cassette was sub cloned into the NheI-AgeI site. To maintain frame between the DCK* suicide gene, and the gene of interest cloned into the Gateway cassette, please make sure to be in-frame with the TACAAAAAA in the attR1 site, and the TACAAAAAA in the attR2 site.
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersBlasticidin
Growth in Bacteria
-
Bacterial Resistance(s)Chloramphenicol and Ampicillin, 25 & 100 μg/mL
-
Growth Temperature30°C
-
Growth Strain(s)ccdB Survival
-
Growth instructionsLonger growth may be needed
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameMutant Deoxycytidine Kinase (DCK*, S74E R104M D133A)
-
SpeciesH. sapiens (human)
-
Insert Size (bp)778
-
MutationS74E R104M D133A
-
GenBank IDNM_000788.3
-
Entrez GeneDCK
-
Tag
/ Fusion Protein
- V5 (C terminal on backbone)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byMutant deoxycytidine kinase was the kind gift of the Medin Lab
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLX304-DCK*-GW-IRES-GFP was a gift from William Kaelin (Addgene plasmid # 176289 ; http://n2t.net/addgene:176289 ; RRID:Addgene_176289) -
For your References section:
Targeting oncoproteins with a positive selection assay for protein degraders. Koduri V, Duplaquet L, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, Ott CJ, Zhang T, Donovan KA, Fischer ES, Gygi SP, Gray NS, Bradner J, Medin JA, Buhrlage SJ, Oser MG, Kaelin WG Jr. Sci Adv. 2021 Feb 5;7(6). pii: 7/6/eabd6263. doi: 10.1126/sciadv.abd6263. Print 2021 Feb. 10.1126/sciadv.abd6263 PubMed 33547076